Albemarle Co. (NYSE:ALB)‘s stock had its “equal weight” rating reiterated by analysts at Morgan Stanley in a report released on Thursday. They presently have a $100.00 price target on the specialty chemicals company’s stock, up from their previous price target of $72.00. Morgan Stanley’s target price would indicate a potential downside of 11.18% from the stock’s current price.

ALB has been the topic of several other research reports. Robert W. Baird restated an “outperform” rating and issued a $125.00 target price on shares of Albemarle in a report on Friday, March 17th. Royal Bank of Canada restated an “outperform” rating and issued a $130.00 target price (up previously from $114.00) on shares of Albemarle in a report on Thursday, March 2nd. Instinet raised their target price on shares of Albemarle from $102.00 to $118.00 and gave the stock a “buy” rating in a report on Wednesday, March 1st. Zacks Investment Research upgraded shares of Albemarle from a “hold” rating to a “buy” rating and set a $117.00 target price on the stock in a report on Monday, March 27th. Finally, Aegis initiated coverage on shares of Albemarle in a report on Friday, February 17th. They issued a “buy” rating and a $108.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $115.64.

Analyst Recommendations for Albemarle (NYSE:ALB)

Albemarle (NYSE:ALB) traded up 0.48% during midday trading on Thursday, hitting $112.59. 636,067 shares of the company were exchanged. Albemarle has a 1-year low of $74.86 and a 1-year high of $113.70. The stock has a 50 day moving average of $108.41 and a 200-day moving average of $97.19. The stock has a market capitalization of $12.47 billion, a price-to-earnings ratio of 27.36 and a beta of 1.41.

Albemarle (NYSE:ALB) last issued its earnings results on Wednesday, May 3rd. The specialty chemicals company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.10. Albemarle had a net margin of 6.92% and a return on equity of 14.38%. The company had revenue of $722.06 million for the quarter, compared to analysts’ expectations of $678.74 million. Equities analysts expect that Albemarle will post $4.36 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 3rd. Shareholders of record on Thursday, June 15th will be given a $0.32 dividend. The ex-dividend date is Tuesday, June 13th. This represents a $1.28 annualized dividend and a yield of 1.14%. Albemarle’s payout ratio is presently 63.54%.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/05/25/albemarle-co-alb-rating-reiterated-by-morgan-stanley.html.

Several hedge funds have recently made changes to their positions in the stock. Sumitomo Mitsui Asset Management Company LTD increased its stake in shares of Albemarle by 10.7% in the third quarter. Sumitomo Mitsui Asset Management Company LTD now owns 8,626 shares of the specialty chemicals company’s stock valued at $737,000 after buying an additional 832 shares during the last quarter. Quantitative Investment Management LLC purchased a new stake in shares of Albemarle during the third quarter valued at approximately $8,574,000. Hanseatic Management Services Inc. increased its stake in shares of Albemarle by 21.7% in the third quarter. Hanseatic Management Services Inc. now owns 28,623 shares of the specialty chemicals company’s stock valued at $2,447,000 after buying an additional 5,101 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. purchased a new stake in shares of Albemarle during the third quarter valued at approximately $104,000. Finally, Nomura Asset Management Co. Ltd. increased its stake in shares of Albemarle by 3.1% in the third quarter. Nomura Asset Management Co. Ltd. now owns 13,210 shares of the specialty chemicals company’s stock valued at $1,129,000 after buying an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 86.50% of the company’s stock.

About Albemarle

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

12 Month Chart for NYSE:ALB

Receive News & Ratings for Albemarle Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Co. and related companies with MarketBeat.com's FREE daily email newsletter.